Status:
COMPLETED
Parathyroidectomy in Endstage Renal Disease
Lead Sponsor:
The University of Hong Kong
Conditions:
Endstage Renal Disease
Eligibility:
All Genders
18-80 years
Phase:
NA
Brief Summary
To test the hypothesis that total parathyroidectomy retards cardiovascular calcification, improves bone mineral density, reduces cardiac hypertrophy and arterial stiffening in end-stage renal disease ...
Detailed Description
Secondary hyperparathyroidism (SHPT) in patients with end-stage renal disease contributes to increased cardiovascular morbidity and mortality via different mechanisms. Uncontrolled hyperparathyroidism...
Eligibility Criteria
Inclusion
- Endstage renal disease patients receiving either long-term hemodialysis or peritoneal dialysis treatment, with elevated intact parathyroid hormone (iPTH) levels \> 500pg/ml on two or more occasions.
- Patients with parathyroid nodular or diffuse hyperplasia identified by ultrasound imaging or radioisotope scan.
- Patients who provide informed consent for the study.
Exclusion
- Patients with significant background valvular heart disease
- Patients who are unfit for general anaesthesia
- Patients with acute myocardial infarction within recent two months
- Patients with poor general condition
- Patients with plans for living related kidney transplant within 1 year
- Patients with previous history of parathyroidectomy
- Patients with calciphylaxis
- Patients with underlying active malignancy
- Patients with contraindication for MRI
Key Trial Info
Start Date :
March 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2012
Estimated Enrollment :
122 Patients enrolled
Trial Details
Trial ID
NCT00745719
Start Date
March 1 2007
End Date
January 1 2012
Last Update
August 5 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Queen Mary Hospital, Tung Wah Hospital
Hong Kong, Hong Kong, 0000